Located in Basel (Switzerland), NBE-Therapeutics’ vision is to become an internationally recognized leader and pioneer for the development of innovative and effective antibody-based medicines, with initially a strong focus on developing Antibody- drug Conjugates (ADCs) for the treatment of cancer.
In order to achieve this, NBE Therapeutics has developed potent antibody discovery and specific drug conjugation technologies and plans to utilize these pioneering technologies for the development of a robust therapeutic antibody and ADC drug pipeline, while continuing the development of its enabling technology platforms. The company is financially backed by the Boehringer Ingelheim Venture Fund.
Technology Parc Basel
Hochbergerstrasse 60C
CH-4057 Basel
Switzerland
Web: NBE Therapeutics
